4D Molecular Therapeutics (NASDAQ:FDMT) Rating Lowered to "Strong Sell" at Wall Street Zen

4D Molecular Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded 4D Molecular Therapeutics from “sell” to “strong sell,” contrasting with the broader analyst consensus of “Moderate Buy” from 10 Buy ratings and one Sell rating; the consensus price target is $30.22.
  • The company reported a quarterly loss of $1.08 per share, slightly worse than the $1.05 loss analysts expected. Revenue of $4.14 million was roughly in line with estimates.
  • Shares were reported down 4.6%, opening at $10.23. Insiders sold 120,520 shares worth about $1.62 million over the prior three months.
  • Five stocks to consider instead of 4D Molecular Therapeutics.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other brokerages also recently commented on FDMT. Bank of America boosted their price objective on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the company a "buy" rating in a research report on Tuesday, September 29th. B. Riley Financial restated a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. Chardan Capital dropped their price objective on 4D Molecular Therapeutics from $26.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, October 6th. The Goldman Sachs Group reaffirmed a "buy" rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, October 22nd. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $30.22.

Get Our Latest Stock Report on FDMT

4D Molecular Therapeutics Trading Down 4.6%

4D Molecular Therapeutics stock opened at $10.23 on Friday. The firm has a market capitalization of $576.77 million, a price-to-earnings ratio of -3.79 and a beta of 2.92. The company has a 50 day moving average price of $12.80 and a 200 day moving average price of $11.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.15 and a current ratio of 6.15. 4D Molecular Therapeutics has a 52 week low of $6.96 and a 52 week high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.03). 4D Molecular Therapeutics had a negative net margin of 208.57% and a negative return on equity of 47.06%. The business had revenue of $4.14 million for the quarter, compared to analyst estimates of $4.13 million. Research analysts forecast that 4D Molecular Therapeutics will post -4.21 EPS for the current year.

Insiders Place Their Bets

In other 4D Molecular Therapeutics news, insider David Kirn sold 58,333 shares of the company's stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $12.92, for a total transaction of $753,662.36. Following the completion of the sale, the insider owned 709,153 shares of the company's stock, valued at $9,162,256.76. This represents a 7.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders sold 120,520 shares of company stock valued at $1,615,978. 7.90% of the stock is currently owned by insiders.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Jupiter Topco LLC acquired a new position in shares of 4D Molecular Therapeutics during the 2nd quarter worth about $76,466,000. Janus Henderson Group PLC boosted its stake in 4D Molecular Therapeutics by 13.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company's stock valued at $48,868,000 after purchasing an additional 611,276 shares during the period. BlackRock Inc. bought a new stake in 4D Molecular Therapeutics during the 2nd quarter valued at approximately $60,463,000. Trails Edge Capital Partners LP acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $29,631,296. Finally, Bank of America Corp DE acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $14,905,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, Inc. is a biotechnology company developing genetic medicines for serious diseases. Its research focuses on adeno-associated virus (AAV) gene therapies, which use engineered viral vectors to deliver therapeutic genetic material to cells. The company's proprietary Therapeutic Vector Evolution platform is designed to create AAV vectors with targeted properties, including the ability to reach specific tissues. Its investigational programs have included treatments for retinal diseases, cystic fibrosis and Fabry disease.

See Also

Analyst Recommendations for 4D Molecular Therapeutics (NASDAQ:FDMT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?

Before you consider 4D Molecular Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.

While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines